Stock Research for ALIM


Featured Broker: Ally Invest

Get the due diligence for another stock.


ALIM Stock Chart & Research Data

The ALIM chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALIM chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ALIM Due diligence Resources & Stock Charts

The ALIM stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALIM Detailed Price Forecast - CNN Money CNN View ALIM Detailed Summary - Google Finance
Yahoo View ALIM Detailed Summary - Yahoo! Finance Zacks View ALIM Stock Research & Analysis -

Stock Analysis

TradeIdeas View ALIM Trends & Analysis - Trade-Ideas Barrons View ALIM Major Holders - Barrons
NASDAQ View ALIM Call Transcripts - NASDAQ Seeking View ALIM Breaking News & Analysis - Seeking Alpha
Spotlight View ALIM Annual Report - OTC Report View ALIM OTC Short Report -
TradeKing View ALIM Fundamentals - TradeKing Charts View ALIM SEC Filings - Bar Chart
WSJ View Historical Prices for ALIM - The WSJ Morningstar View Performance/Total Return for ALIM - Morningstar
MarketWatch View the Analyst Estimates for ALIM - MarketWatch CNBC View the Earnings History for ALIM - CNBC
StockMarketWatch View the ALIM Earnings - StockMarketWatch MacroAxis View ALIM Buy or Sell Recommendations - MacroAxis
Bullish View the ALIM Bullish Patterns - American Bulls Short Pains View ALIM Short Pain Metrics -

Social Media Mentions

StockTwits View ALIM Stock Mentions - StockTwits PennyStocks View ALIM Stock Mentions - PennyStockTweets
Twitter View ALIM Stock Mentions - Twitter Invest Hub View ALIM Investment Forum News - Investor Hub
Yahoo View ALIM Stock Mentions - Yahoo! Message Board Seeking Alpha View ALIM Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ALIM - Insider Cow View Insider Transactions for ALIM - Insider Cow
CNBC View ALIM Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALIM - OTC Markets
Yahoo View Insider Transactions for ALIM - Yahoo! Finance NASDAQ View Institutional Holdings for ALIM - NASDAQ

Stock Charts

FinViz View ALIM Stock Insight & Charts - StockCharts View ALIM Investment Charts -
BarChart View ALIM Stock Overview & Charts - BarChart Trading View View ALIM User Generated Charts - Trading View

Latest Financial News for ALIM

2 Healthcare Stocks Set to Rally into the New Year
Posted on Friday January 10, 2020

The psychology of investing presents an interesting conundrum. When a stock soars, the natural tendency is to want to get in on the action, as the FOMO kicks in and the allure of further gains is hard to resist. This is often the wrong choice as the stock will likely be sold off at a premium to latecomers.Conversely, a beaten-down stock induces tremors of fear. The inevitable concern about the stock’s low valuation and negative market sentiment can cause potential investors to avoid backing what appears to be a losing horse. This is sometimes the case, but other times share price weakness represents the best time to get in before a stock sets off on its upward trajectory.So how can you tell the losers from the winners? While nothing is certain, the experts on Wall Street can lend a helping hand. In a recent note to clients, B. Riley FBR analyst Andrew D’Silva highlights stocks in the healthcare sector which he thinks are set to make headway in 2020.“Each company either exited 2019 on a strong footing, where momentum is poised to carry over into 2020, or has fallen out of favor, but execution will result in a reversal,” the analyst commented.Using TipRanks’ Stock Comparison tool, we were able to zoom in on 2 of D’Silva’s choices. Whether beaten-down or flying high, all have plenty of room for upside, and all currently have a Strong Buy consensus rating from the Street. Let's take a closer look:Alimera Sciences (ALIM)Alimera Sciences had a miserable 2019. The retinal disease focused company lost 30% of its share price over the year. So far, 2020 has not been kinder, either. The share price is down by almost 10% year-to-date.So, should investors stay away? Absolutely not, says D’Silva. Now is the time to reassess the biopharma’s potential.The drop, he says, was instigated by the significant impact of 2Q19 results missing expectations, which were mostly attributed to a significant loss of domestic sales force. During 1H19, “several companies launched ophthalmic offerings and established/expanded their sales teams.” The numerous employment opportunities contributed to a depletion of Alimera’s own sales team.“We believe this compounded investor working capital concerns, as ALIM's $40 million term loan's interest-only period was scheduled to end within a year's time,” D’Silva noted.However, the analyst expects a “significant reversal this year.” He cited a resolution to the company’s sales force turnover issues, an expanding international footprint, and the “significant milestone” of management’s positive 2020 adjusted EBITDA guidance as reasons for the anticipated turnaround. Furthermore, a new debt refinancing arrangement “cleared a significant working capital overhang.”D’Silva noted, “While we expected that the company would refinance its term loan, we believe this should remove a significant trading overhang related to investor fears that ALIM would need to raise capital through a highly dilutive equity financing to fund operations and meet its debt obligation.”D'Silva, therefore, reiterated a Buy rating on Alimera along with a price target of $24. With ALIM currently trading at $6.91, the upside potential comes in at a massive 243%. (To watch D’Silva’s track record, click here)All in all, three analysts are currently keeping track of the eye disease specialist and all three see better days ahead too, rating the stock a Buy. With an average price target of $20.50, the figure suggests potential upside of nearly 200%. (See Alimera price targets and analyst ratings on TipRanks)CytoSorbents Corporation (CTSO)In a similar vein to Alimera, CytoSorbents is a beaten-down stock, displaying even further wreckage. It lost 52% of its share price during last year’s bull run.CTSO’s blood purification technologies are used to control deadly inflammation in critically-ill and cardiac surgery patients. After exhibiting revenue growth of 51% in 2018, the growth curve slowed down to 9% year-over-year in the first three quarters of 2019.D’Silva explained, “While the slower top-line growth could be concerning at first glance, the two primary reasons for the slowdown were related to two CS distributors and Fresenius Medical Care—which, together, accounted for ~15%-20% of the CTSO top line in 2018—entering 2019 with excess inventory, as well as CTSO running into sales-force bandwidth issues in its largest market, Germany.”With CTSO commencing sales in Poland, Sweden, Denmark, Norway, and the Netherlands, D’Silva foresees a turnaround in the months ahead.“While we don't anticipate CTSO realized significant benefits from new direct sales regions in 4Q19, as most new sales hires were onboarded in 2H19, we do expect CTSO's expanded footprint to provide a significant benefit this year… Meanwhile, We believe there are numerous clinical and regulatory catalysts are on the horizon that should be significant value drivers for the stock if successful,” said the analyst.As a result, D’Silva kept his Buy rating and supports it with an ambitious $12 price target. Attaining this number will provide a very healthy 210% gain in the next twelve months.Does the Street agree? Those who are taking notice certainly do. 3 Buy ratings and no Holds or Sells add up to a unanimous Strong Buy consensus rating. The recommendation comes alongside an average price target of $11 and implies upside potential of 176%. (See CytoSorbents stock-price forecast and analyst ratings)

Alimera Sciences Refinances Its Debt Facility With Solar Capital
Posted on Monday January 06, 2020

The amount of the new funding includes an initial tranche of $42.5 million used to repay the current facility, including principal, prepayment fees and accrued interest, and another $2.5 million tranche that will be available if Alimera achieves $30.0 million in revenue for any trailing six-month period ending on or before November 30, 2020. The interest-only period may be extended an additional six months if Alimera achieves $34.5 million in revenue for any trailing six-month period ending on or before June 30, 2022. “We are pleased that Solar Capital has agreed to extend our relationship and continue working with Alimera in support of our future growth,” said Rick Eiswirth, Alimera’s president and chief executive officer.

Did Hedge Funds Drop The Ball On Alimera Sciences Inc (ALIM) ?
Posted on Tuesday December 17, 2019

"The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among the strongest for many decades. Interest rates are paused at very low levels, and the risk of significant increases in the medium term seems low. Financing for transactions is freely available to good borrowers, […]

Almira Sciences, Inc 13D filing
Posted on Wednesday December 11, 2019

Ronald L Chez, a private investor, files a 13D for Alimera Sciences, Inc. (NASDAQ: ALIM). Alimera returns to growth in the 3rd quarter and expects continued progress in the 4th quarter. The Company is in a strong position to succeed with their unique approach to DME.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.